City Therapeutics, Inc. (NASDAQ:CTY – Get Free Report) major shareholder Arch Venture Partners Xii, Llc purchased 170,000 shares of the business’s stock in a transaction dated Monday, October 19th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $3,060,000.00. Following the acquisition, the insider directly owned 13,692,507 shares in the company, valued at $246,465,126. This represents a 1.26% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
City Therapeutics Trading Down 4.2%
NASDAQ:CTY traded down $0.94 during trading hours on Monday, reaching $21.46. The company’s stock had a trading volume of 302,365 shares. City Therapeutics, Inc. has a one year low of $20.50 and a one year high of $23.88.
City Therapeutics Company Profile
See Also
- Five stocks we like better than City Therapeutics
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Receive News & Ratings for City Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for City Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
